Statins may help prolong survival in NSCLC resection

October 22, 2012

Patients who have undergone resection for non-small cell lung cancer (NSCLC) may improve their overall survival and reduce the risk of recurrence by taking statins.

Researchers from Northwestern University Feinberg School of Medicine, Chicago, and Penn State Hershey Cancer Institute followed 803 patients who underwent resection for , of which 315 were using statins.

Results showed that statin use was associated with a significantly lower local recurrence rate and significantly higher overall survival compared with non-statin users.

Researchers conclude that prospective studies are needed to assess the role of statin therapy as an adjunct to current multimodality regimens.

This study was presented during CHEST 2012, the annual meeting of the , held October 20 – 25, in Atlanta, Georgia.

Related Stories

Study finds no link between statins and cancer risk

July 25, 2011

(Medical Xpress) -- A new study published in the Journal of the American College of Cardiology reports that, contrary to previous studies, the use of cholesterol reducing statin drugs does not increase the risk of patients ...

Recommended for you

New treatment options for a fatal leukemia

July 27, 2015

In industrialized countries like in Europe, acute lymphoblastic leukemia is the most common form of cancer in children. An international research consortium lead by pediatric oncologists from the Universities of Zurich and ...

Modified DNA building blocks are cancer's Achilles heel

July 22, 2015

In studying how cells recycle the building blocks of DNA, Ludwig Cancer Research scientists have discovered a potential therapeutic strategy for cancer. They found that normal cells have highly selective mechanisms to ensure ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.